Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. - Wikidata - wikimedia - TriplyDB

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

http://www.wikidata.org/entity/Q44712034

about

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours Somatostatin receptor based imaging and radionuclide therapy.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.A nuclear chocolate box: the periodic table of nuclear medicine.Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Radionuclide Therapy for Neuroendocrine Tumors.Modular syntheses of H₄octapa and H₂dedpa, and yttrium coordination chemistry relevant to ⁸⁶Y/⁹⁰Y radiopharmaceuticals.The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.Theranostics in nuclear medicine practice The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.Towards tailored radiopeptide therapy

P2860

Q28247667-37766F33-F7F5-4A77-A90A-C9E088EAAA67 Q35296661-FC787EBB-E774-43C7-972E-C79A0C98B314 Q35675435-59A879ED-9A53-4A90-BCB6-F1B417FF65F9 Q36644325-5524EEC2-447E-49D3-AACC-5F8663E79EA9 Q38269216-DA52002E-3215-4BC8-869A-D2F886A59D99 Q38625614-216A9F3C-14F1-4ACC-85E6-87EAEC56D2DE Q38909078-48D9B95D-C956-4A3F-82BD-3162E0428AD1 Q39144880-A1280951-EF02-4738-888F-812E536EF51E Q39221164-EDB32B12-D563-4B88-BE9F-8D61C835CA49 Q40616326-FD55CBA9-5E41-4B59-9FA1-BF650AC85A01 Q41244010-DD430568-1D01-4701-BE54-3E653C736C82 Q42373162-69BFDCF4-5F1C-499A-A74F-8DBBA15908E7 Q48148957-369A70C3-DC3B-4950-99E7-E669AE1426DD Q51242700-94E43068-75DE-471D-9242-31FAF3F6A069 Q56761887-35AC47E2-9373-43DB-BA69-F0E66506A9CE

P2860

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

http://www.wikidata.org/entity/Q44712034

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@en

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@nl

type

label

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@en

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@nl

prefLabel

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@en

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@nl

P1433

Q44712034-049E78D3-7461-4F30-9C00-D941020CF008

P1476

Q44712034-507F568A-09A4-4CE3-A76D-AE39DFFE274B

P2093

Q44712034-00DA36C8-CF6D-48C4-AA78-3D5A5140ACB8

Q44712034-0327CF48-C766-4172-8E77-DB403EC957CB

Q44712034-0C9214D0-7FA6-4E86-82A8-8EF6DEA28DC1

Q44712034-38382E6A-E63C-494E-A8E3-75CC0D1457AF

Q44712034-49C27E0B-6D7A-4E4A-A823-B498B3CD99E6

Q44712034-4BCE1710-6C8A-4247-B535-1D2FDCE7205D

Q44712034-7A00E860-3D16-4249-B43E-58808AC626D5

Q44712034-BC4DBC02-DB45-44BD-9615-219B16E65DA0

Q44712034-C506DAE0-61E0-4021-A13F-A058B587E53F

Q44712034-F6089778-585A-49A6-AC12-1800F0C83B8D

P2860

Q44712034-069DE263-42E9-4A55-925D-1520F6571E59

Q44712034-26603406-ED30-4A05-8271-AB5665341444

Q44712034-27F0406B-454B-450C-B2FC-41014942FCEC

Q44712034-2E449D6B-ECD1-46B5-B967-3BA73E819029

Q44712034-415AD11A-7D7E-436E-82F0-C3B9D35EE5DA

Q44712034-447816F0-D194-49E7-8FB4-50165AB53B78

Q44712034-4C672A5F-C0D2-4DDB-A5D0-363E54964BFE

Q44712034-5AF46952-E42F-416D-9753-940E78D995D7

Q44712034-77C17E1C-D2F4-44D0-BB0A-BC93110BCC7C

Q44712034-85843889-ED1E-4D70-9328-D1BD81D75EA6

P2888

Q44712034-70B2D15C-21D6-4954-9077-F37B753D3654

P304

Q44712034-511FFFBD-55F5-4EEF-930D-5AF8E15B623D

P31

Q44712034-2CF84C72-B412-4393-86A9-89AAB7F6E563

P356

Q44712034-9F71E71E-912F-4799-827A-20F182C01910

P433

Q44712034-5F2196BD-E5EB-498B-BE84-4DA5EE348948

P478

Q44712034-0872C9B7-C6B3-48CC-A26E-5962DE81752C

P50

Q44712034-074A3F3F-F91E-4E44-9CFF-B536DD4E8115

Q44712034-75DC4998-8BFD-416E-A3AD-3398A2C028FC

P577

Q44712034-4358C1B1-B88D-4705-B45B-3EBFD8C8FB17

P5875

Q44712034-8360D881-536C-4CE5-9B2A-DEBCA20431D6

P698

Q44712034-49DD456B-504F-4B47-860F-0BF162644782

P356

S00259-013-2559-8

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Somatostatin-based radiopeptid ...... TOC in neuroendocrine tumours.

@en

P2093

A Romer

http://www.w3.org/2001/XMLSchema#string

C Rochlitz

http://www.w3.org/2001/XMLSchema#string

C Schindler

http://www.w3.org/2001/XMLSchema#string

D Seiler

http://www.w3.org/2001/XMLSchema#string

H R Maecke

http://www.w3.org/2001/XMLSchema#string

J Müller-Brand

http://www.w3.org/2001/XMLSchema#string

M T Koller

http://www.w3.org/2001/XMLSchema#string

N Marincek

http://www.w3.org/2001/XMLSchema#string

P Brunner

http://www.w3.org/2001/XMLSchema#string

Q K T Ng

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Peptide receptors as molecular targets for cancer diagnosis and therapy.

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Tutorial in biostatistics: competing risks and multi-state models.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Cancer: antitumor effects of octreotide LAR, a somatostatin analog.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

P2888

s00259-013-2559-8

P304

214-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-013-2559-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257301394

http://www.w3.org/2001/XMLSchema#string

P698

24085501

http://www.w3.org/2001/XMLSchema#string